Clinical Trial Detail

NCT ID NCT03853317
Title Evaluate Efficacy of Avelumab, haNK and N-803 in Subjects With Progressed MCC on or After Checkpoint Inhibitor Therapy.
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Altor BioScience

Merkel cell carcinoma


ALT-803 + Avelumab + haNK cells

Age Groups: senior adult

No variant requirements are available.